Celldex Therapeutics Q2 EPS $(0.54) Beats $(0.60) Estimate, Sales $2.50M Beat $820.43K Estimate

Author: Benzinga Newsdesk | August 08, 2024 05:08pm
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 16.92 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $2.50 million which beat the analyst consensus estimate of $820.43 thousand by 204.47 percent. This is a 832.09 percent increase over sales of $268.00 thousand the same period last year.

Posted In: CLDX